| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 55513-0956-21 | 55513-0956 | Panitumumab | Vectibix | 400.0 mg/20mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 1, 2025 | In Use | |
| 63850-0132-02 | 63850-0132 | Pomalidomide | Pomalidomide | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Nov 1, 2025 | In Use | |
| 57894-0111-02 | 57894-0111 | ciltacabtagene autoleucel | CARVYKTI | 100000000.0 1/1 | Immunotherapy | CAR-T | BCMA | Intravenous | Feb 28, 2022 | In Use | |
| 61314-0240-63 | 61314-0240 | Denosumab | JUBBONTI | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
| 00093-6126-64 | 00093-6126 | Imiquimod | Imiquimod | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Dec 19, 2013 | Apr 30, 2015 | No Longer Used | |
| 50242-0917-86 | 50242-0917 | Atezolizumab | Tecentriq | 1200.0 mg/20mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Aug 11, 2016 | In Use | |
| 51991-0344-01 | 51991-0344 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2025 | In Use | |
| 47781-0483-28 | 47781-0483 | Lenalidomide | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 65219-0672-01 | 65219-0672 | Denosumab | BOMYNTRA | 70.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 30, 2025 | In Use | |
| 57894-0505-05 | 57894-0505 | Daratumumab | Darzalex IV | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Oct 15, 2021 | In Use | |
| 59651-0346-07 | 59651-0346 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 73776-0001-12 | 73776-0001 | Lifileucel | AMTAGVI | 72000000000.0 1/500mL | Immunotherapy | Tumor Infiltrating Lymphocytes (TILs) | CD4+T, CD8+T | Intravenous | Feb 16, 2024 | In Use | |
| 00085-1235-01 | 00085-1235 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Jun 4, 1986 | Oct 3, 2010 | No Longer Used | ||
| 51991-0346-01 | 51991-0346 | Pomalidomide | Pomalidomide | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2025 | In Use | |
| 63850-0133-01 | 63850-0133 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Nov 1, 2025 | In Use | |
| 63304-0045-01 | 63304-0045 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 12, 2023 | In Use | |
| 59651-0346-01 | 59651-0346 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 60219-1717-01 | 60219-1717 | Lenalidomide | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 12, 2025 | In Use | |
| 83047-0410-04 | 83047-0410 | Obecabtagene autoleucel | AUCATZYL | 10000000.0 /1, 100000000.0 /1, 300000000.0 /1 | Immunotherapy | CAR-T | CD19 | Intravenous | Nov 8, 2024 | In Use | |
| 72606-0012-10 | 72606-0012 | Bevacizumab-adcd | Vegzelma | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Apr 3, 2023 | In Use | |
| 70771-1677-01 | 70771-1677 | LENALIDOMIDE | LENALIDOMIDE | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
| 00085-4351-01 | 00085-4351 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Aug 11, 2014 | In Use | |||
| 00378-1942-01 | 00378-1942 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
| 50242-0917-01 | 50242-0917 | Atezolizumab | Tecentriq | 1200.0 mg/20mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | May 18, 2016 | In Use | |
| 55135-0132-01 | 55135-0132 | SACITUZUMAB GOVITECAN | TRODELVY | 180.0 mg/1 | Immunotherapy | Drug Antibody Conjugate | Trop-2 | Intravenous | Apr 23, 2020 | In Use |
Found 12159 results — Export these results
Home